Beta-blockers, ACE-I/ARBs, statins US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Beta-blockers, ACE-I/ARBs, statins. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 1: A 55-year-old man comes to the physician because of a 4-month history of episodic, pressure-like chest pain. The chest pain occurs when he is walking up stairs and improves with rest. He has hypertension and type 2 diabetes mellitus. His father died from a myocardial infarction at the age of 50 years. Current medications include hydrochlorothiazide and metformin. His pulse is 85/min, respirations are 12/min, and blood pressure is 140/90 mm Hg. Cardiac examination shows normal heart sounds without any murmurs, rubs, or gallops. An ECG shows high amplitude of the S wave in lead V3. An exercise stress test is performed but stopped after 4 minutes because the patient experiences chest pain. An ECG obtained during the stress test shows sinus tachycardia and ST-segment depressions in leads V1–V4. Which of the following is the most appropriate long-term pharmacotherapy to reduce the frequency of symptoms in this patient?
- A. Metoprolol (Correct Answer)
- B. Clopidogrel
- C. Aspirin
- D. Nitroglycerin
- E. Isosorbide mononitrate
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Metoprolol***
- **Beta-blockers** like metoprolol are first-line agents for **symptom relief** in stable angina by reducing myocardial oxygen demand.
- They decrease **heart rate**, **blood pressure**, and **myocardial contractility**, thereby reducing the frequency and severity of anginal episodes.
*Clopidogrel*
- **Clopidogrel** is an antiplatelet agent used primarily to prevent **thrombotic events** in patients with established cardiovascular disease or acute coronary syndromes.
- It does not directly reduce the frequency of anginal symptoms, but rather prevents progression to **myocardial infarction** or **stroke**.
*Aspirin*
- **Aspirin** is an antiplatelet medication used for **secondary prevention** of cardiovascular events by inhibiting platelet aggregation.
- While crucial for reducing cardiovascular risk, it does not directly alleviate the **frequency of anginal symptoms** themselves.
*Nitroglycerin*
- **Nitroglycerin** is a short-acting nitrate used to provide **immediate relief** of anginal pain during an acute episode.
- It is not a long-term pharmacotherapy for reducing the *frequency* of symptoms.
*Isosorbide mononitrate*
- **Isosorbide mononitrate** is a long-acting nitrate used to *prevent* angina, but it is typically a **second-line agent** after beta-blockers due to potential for **tolerance** and side effects.
- While it can reduce symptom frequency, beta-blockers are generally preferred as initial long-term therapy for symptom control.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 2: A 62-year-old man comes to the physician for an annual health maintenance examination. He has a history of stable angina, gout, and hypertension. His medications include lisinopril and aspirin. He has smoked a pack of cigarettes daily for 20 years. He drinks 5–6 beers on the weekends. His blood pressure is 150/85 mm Hg. Laboratory studies show a total cholesterol of 276 mg/dL with an elevated low-density lipoprotein (LDL) concentration and low high-density lipoprotein (HDL) concentration. Administration of which of the following agents is the most appropriate next step in management?
- A. Peroxisome proliferator-activated receptor alpha activator
- B. Cholesterol absorption inhibitor
- C. HMG-CoA reductase inhibitor (Correct Answer)
- D. Bile acid resin
- E. Proprotein convertase subtilisin kexin 9 inhibitor
Beta-blockers, ACE-I/ARBs, statins Explanation: ***HMG-CoA reductase inhibitor***
- This patient has a history of **stable angina**, **hypertension**, and **dyslipidemia** (elevated LDL, low HDL), placing him at high risk for cardiovascular events. **Statins** (HMG-CoA reductase inhibitors) are first-line therapy for reducing LDL cholesterol and cardiovascular risk in such patients.
- They work by **inhibiting the rate-limiting step of cholesterol synthesis** in the liver, leading to an upregulation of LDL receptors and increased clearance of LDL from the blood.
*Peroxisome proliferator-activated receptor alpha activator*
- These agents, like **fibrates**, primarily reduce **triglycerides** and can increase HDL, but they are less effective at lowering LDL compared to statins.
- They are typically used for patients with **severe hypertriglyceridemia** or in combination with statins if significant HDL or triglyceride issues persist.
*Cholesterol absorption inhibitor*
- **Ezetimibe** works by preventing the absorption of cholesterol in the small intestine.
- While effective at lowering LDL, it is generally used as an **add-on therapy to statins** or for patients unable to tolerate statins, rather than as a first-line agent in high-risk patients.
*Bile acid resin*
- **Bile acid sequestrants** (e.g., cholestyramine) work by binding bile acids in the intestine, preventing their reabsorption and increasing their excretion.
- This leads to increased hepatic synthesis of bile acids from cholesterol, lowering LDL, but they can cause **gastrointestinal side effects** and are generally less potent and less tolerated than statins.
*Proprotein convertase subtilisin kexin 9 inhibitor*
- **PCSK9 inhibitors** are highly effective at lowering LDL cholesterol by preventing the degradation of LDL receptors, thereby increasing LDL clearance.
- They are typically reserved for patients with **familial hypercholesterolemia** or those with established cardiovascular disease who have not achieved adequate LDL lowering with maximally tolerated statin therapy, often due to their high cost and subcutaneous administration.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 3: A 55-year-old man comes to the physician because of intermittent palpitations that occur when he is stressed, exercising, or when he drinks alcohol. Physical examination shows an irregularly irregular pulse. An ECG shows irregular QRS complexes without any discrete P waves. Pharmacotherapy with carvedilol is initiated for his condition. Compared to treatment with propranolol, which of the following adverse effects is most likely?
- A. Bradycardia
- B. Bronchospasm
- C. Hyperkalemia
- D. Hypotension (Correct Answer)
- E. Hyperglycemia
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Hypotension***
- **Carvedilol** is a non-selective beta-blocker with additional **alpha-1 adrenergic receptor blocking activity**, which leads to peripheral vasodilation and a greater potential for **hypotension** compared to propranolol (a pure beta-blocker).
- The **alpha-1 blockade** causes a reduction in peripheral vascular resistance, leading to a more pronounced decrease in blood pressure.
*Bradycardia*
- Both carvedilol and propranolol are beta-blockers and can cause **bradycardia** by reducing heart rate.
- However, the question asks for an adverse effect **more likely** with carvedilol compared to propranolol, and while both can cause bradycardia, carvedilol's additional alpha-blocking activity makes hypotension more distinguishing.
*Bronchospasm*
- Both carvedilol and propranolol are **non-selective beta-blockers** (blocking both beta-1 and beta-2 receptors) and can cause **bronchospasm** by blocking beta-2 receptors in the bronchi.
- Therefore, this adverse effect is common to both and not more likely with carvedilol specifically in comparison to propranolol.
*Hyperkalemia*
- Neither carvedilol nor propranolol is directly associated with causing **hyperkalemia** as a primary adverse effect.
- Beta-blockers can sometimes lead to minor shifts in potassium, but it's not a common or more significant side effect compared to others listed.
*Hyperglycemia*
- **Non-selective beta-blockers** like propranolol can impair the recovery from **hypoglycemia** and mask its symptoms.
- While beta-blockers can have some metabolic effects, **hyperglycemia** is not a generally recognized or more prominent adverse effect of carvedilol compared to propranolol.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 4: A 72-year-old man presents to the outpatient clinic today. He has New York Heart Association class III heart failure. His current medications include captopril 20 mg, furosemide 40 mg, potassium chloride 10 mg twice daily, rosuvastatin 20 mg, and aspirin 81 mg. He reports that he generally feels well and has not had any recent worsening of his symptoms. His blood pressure is 132/85 mm Hg and heart rate is 84/min. Physical examination is unremarkable except for trace pitting edema of the bilateral lower extremities. What other medication should be added to his heart failure regimen?
- A. Losartan
- B. Metoprolol tartrate
- C. Isosorbide dinitrate/hydralazine
- D. Metoprolol succinate (Correct Answer)
- E. Digoxin
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Metoprolol succinate***
- Current guidelines recommend adding a **beta-blocker** (specifically metoprolol succinate, carvedilol, or bisoprolol) as part of guideline-directed medical therapy (GDMT) for **NYHA class II-IV heart failure with reduced ejection fraction (HFrEF)**.
- This patient is already on an **ACE inhibitor and diuretic** but is missing a **beta-blocker**, which is a cornerstone of HFrEF therapy.
- Beta-blockers **reduce mortality and morbidity** in HFrEF by counteracting chronic sympathetic activation, improving cardiac remodeling, and reducing heart rate.
- Metoprolol succinate is the **long-acting formulation** preferred for chronic heart failure management.
***Incorrect Option: Losartan***
- The patient is already on an **ACE inhibitor (captopril)**, which acts on the renin-angiotensin-aldosterone system.
- Adding an **ARB (angiotensin receptor blocker)** like losartan to an ACE inhibitor is generally not recommended due to increased risk of hyperkalemia, hypotension, and renal dysfunction without significant additional benefit.
- ARBs are typically used as an alternative when patients cannot tolerate ACE inhibitors (e.g., due to cough or angioedema).
***Incorrect Option: Metoprolol tartrate***
- While metoprolol tartrate is a beta-blocker, it is a **short-acting formulation** typically used for acute conditions like hypertension or angina.
- For **chronic heart failure management**, **long-acting beta-blockers** such as metoprolol succinate are preferred due to sustained therapeutic levels, better adherence, and proven mortality benefit in clinical trials.
***Incorrect Option: Isosorbide dinitrate/hydralazine***
- This combination is primarily indicated for **African American patients with NYHA class III-IV HFrEF** who remain symptomatic despite optimal therapy, or as an alternative in patients who cannot tolerate ACE inhibitors/ARBs.
- While the patient has class III heart failure, he is **not yet on a beta-blocker**, which is a more fundamental component of GDMT and should be added first.
- This combination is typically added as a fourth-line agent.
***Incorrect Option: Digoxin***
- Digoxin is considered for patients with **HFrEF who remain symptomatic** despite optimized therapy with ACE inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists (MRAs).
- It primarily helps **improve symptoms and reduce hospitalizations** but does not reduce mortality.
- Since this patient is not yet on a beta-blocker, adding the beta-blocker takes priority.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 5: A 71-year-old African American man diagnosed with high blood pressure presents to the outpatient clinic. In the clinic, his blood pressure is 161/88 mm Hg with a pulse of 88/min. He has had similar blood pressure measurements in the past, and you initiate captopril. He presents back shortly after initiation with extremely swollen lips, tongue, and face. After captopril is discontinued, what is the most appropriate step for the management of his high blood pressure?
- A. Initiate a beta-blocker
- B. Switch to ramipril
- C. Initiate a thiazide diuretic (Correct Answer)
- D. Reinitiate captopril
- E. Initiate an ARB
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Initiate a thiazide diuretic***
- The patient experienced **angioedema** after taking **captopril**, which is an **ACE inhibitor**. This is a life-threatening adverse effect, and it indicates that all **ACE inhibitors** should be avoided in the future.
- Due to the risk of angioedema, a different class of antihypertensive should be used. Given his African American ethnicity, a **thiazide diuretic** or **calcium channel blocker** would be an appropriate initial choice for monotherapy if hypertension is stage 1, or combination therapy if stage 2 hypertension, otherwise, a second agent, such as a **calcium channel blocker**, can be added.
*Initiate a beta-blocker*
- While beta-blockers are a class of antihypertensive drugs, they are generally not preferred as **first-line monotherapy** for **hypertension**, especially in older African American patients, unless there are specific comorbidities like heart failure or coronary artery disease.
- The most appropriate first-line choice after **ACE inhibitor-induced angioedema** would be a thiazide diuretic or calcium channel blocker, as per ACC/AHA guidelines for primary hypertension.
*Switch to ramipril*
- **Ramipril** is also an **ACE inhibitor**, and the patient experienced **angioedema** with **captopril** (another ACE inhibitor).
- Cross-reactivity and recurrence of angioedema are high with other ACE inhibitors, making this choice extremely dangerous and contraindicated.
*Reinitiate captopril*
- The patient developed **angioedema**, a severe and potentially fatal hypersensitivity reaction, to **captopril**.
- Reinitiating the same drug could lead to recurrent, and potentially more severe, angioedema and is therefore absolutely contraindicated.
*Initiate an ARB*
- **Angiotensin receptor blockers (ARBs)**, while a different class from ACE inhibitors, act on the renin-angiotensin system and carry a **small but significant risk of cross-reactivity** leading to angioedema, especially in patients who have experienced it with an ACE inhibitor.
- Given the life-threatening nature of angioedema, it is generally recommended to avoid ARBs if a patient has a history of ACE inhibitor-induced angioedema.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 6: A 73-year-old man presents to the outpatient clinic complaining of chest pain with exertion. He states that resting for a few minutes usually resolves the chest pain. Currently, he takes 81 mg of aspirin daily. He has a blood pressure of 127/85 mm Hg and heart rate of 75/min. Physical examination reveals regular heart sounds and clear lung sounds bilateral. Which medication regimen below should be added?
- A. Metoprolol and a statin daily. Sublingual nitroglycerin as needed. (Correct Answer)
- B. Clopidogrel and amlodipine daily. Sublingual nitroglycerin as needed.
- C. Amlodipine and a statin daily. Sublingual nitroglycerin as needed.
- D. Amlodipine daily. Sublingual nitroglycerin as needed.
- E. Metoprolol and ranolazine daily. Sublingual nitroglycerin as needed.
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Metoprolol and a statin daily. Sublingual nitroglycerin as needed.***
- This patient presents with symptoms consistent with **stable angina** (**chest pain with exertion, relieved by rest**). The recommended medical therapy includes **antiplatelet agents** (aspirin, already prescribed), **beta-blockers** (metoprolol) for symptom control and improved survival post-MI, and **high-intensity statins** for lipid management and plaque stabilization. **Sublingual nitroglycerin** is crucial for acute symptom relief.
- Beta-blockers like metoprolol decrease myocardial **oxygen demand** by reducing heart rate and contractility, effectively treating angina. Statins are essential for **atherosclerosis management**.
*Clopidogrel and amlodipine daily. Sublingual nitroglycerin as needed.*
- While clopidogrel is an **antiplatelet agent**, aspirin is typically the first-line choice for stable angina unless there's an intolerance or compelling reason for dual antiplatelet therapy (e.g., recent stent placement), which is not indicated here.
- Amlodipine, a **calcium channel blocker**, can be used for angina but is usually a second-line agent if beta-blockers are contraindicated or insufficient; it doesn't offer the mortality benefit seen with beta-blockers post-MI.
*Amlodipine and a statin daily. Sublingual nitroglycerin as needed.*
- This regimen includes a **statin** and sublingual nitroglycerin, which are appropriate. However, it uses amlodipine instead of a beta-blocker, which is generally the preferred initial therapy for angina due to its benefits in reducing myocardial oxygen demand and improving outcomes, especially in patients with a history of MI or heart failure.
- Beta-blockers provide superior **mortality reduction benefits** in patients with coronary artery disease compared to calcium channel blockers.
*Amlodipine daily. Sublingual nitroglycerin as needed.*
- This option misses two critical components of comprehensive treatment for stable angina: a **statin** for lipid management and plaque stabilization, and a **beta-blocker** for primary symptom control and long-term cardiac protection.
- Relying solely on amlodipine and sublingual nitroglycerin would leave the patient incompletely treated for their underlying **coronary artery disease**.
*Metoprolol and ranolazine daily. Sublingual nitroglycerin as needed.*
- This option lacks a **statin**, which is a cornerstone of therapy for stable angina to manage atherosclerosis.
- While metoprolol is appropriate and ranolazine can be used as an add-on therapy for refractory angina, it's not typically a first-line agent and doesn't replace the need for a statin.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 7: A 60-year-old patient is at his physician’s office for a routine health maintenance exam. The patient has a past medical history of osteoarthritis in his right knee and GERD that is well-controlled with over the counter medication. On a fasting lipid profile, he is found to have high cholesterol. The patient is started on daily atorvastatin to reduce his risk of cardiovascular disease. What is the major apolipoprotein found on the lipoprotein most directly affected by his statin medication?
- A. Apolipoprotein C-II
- B. Apolipoprotein B-100 (Correct Answer)
- C. Apolipoprotein A-I
- D. Apolipoprotein B-48
- E. Apolipoprotein E
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Apolipoprotein B-100***
- Statins primarily reduce **LDL-C** levels by inhibiting **HMG-CoA reductase**, leading to increased LDL receptor expression and clearance of LDL particles from the blood.
- **Apolipoprotein B-100** is the main apolipoprotein found on **LDL** and is crucial for its binding to the LDL receptor.
*Apolipoprotein C-II*
- This apolipoprotein activates **lipoprotein lipase**, which is involved in the hydrolysis of triglycerides in **chylomicrons** and **VLDL**, not directly targeted by statins.
- While statins can indirectly affect VLDL, ApoC-II is not the major apolipoprotein of the lipoprotein most directly affected by statins.
*Apolipoprotein A-I*
- **Apolipoprotein A-I** is the primary apolipoprotein found on **HDL**, which is involved in **reverse cholesterol transport**.
- While statins can have a modest effect on increasing HDL, their primary action is on reducing LDL.
*Apolipoprotein B-48*
- **Apolipoprotein B-48** is found exclusively on **chylomicrons**, which are responsible for the transport of exogenous dietary fats from the intestines.
- Chylomicrons are not the primary target of statin therapy, which focuses on endogenous cholesterol metabolism.
*Apolipoprotein E*
- **Apolipoprotein E** is found on chylomicrons, VLDL, and HDL and plays a role in receptor binding for their clearance from circulation.
- While important for lipoprotein metabolism, it is not the *major* apolipoprotein of the lipoprotein most *directly* affected by statins (LDL).
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 8: A 56-year-old patient developed excruciating chest discomfort in the past 72 hours, relieved by GTN spray. Troponin I is normal, and the ECG shows features of left ventricular hypertrophy (LVH) with T wave flattening. The patient is already on statins, aspirin, and metoprolol 50 mg . What is the next best step in management?
- A. LMWH (Low Molecular Weight Heparin)
- B. Increase beta blocker dose
- C. IV NTG Drip
- D. Add Clopidogrel (Correct Answer)
- E. Arrange urgent coronary angiography
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Add Clopidogrel***
- The patient presents with **unstable angina** (chest discomfort relieved by GTN, normal troponin, and ECG changes indicative of ischemia) and is already on aspirin, statins, and a beta-blocker.
- Adding **clopidogrel** (or another P2Y12 inhibitor) is crucial for **dual antiplatelet therapy (DAPT)**, which is a cornerstone in the management of unstable angina/NSTEMI to prevent further thrombotic events.
- This is the **immediate next step** to optimize medical therapy before considering invasive strategies.
*LMWH (Low Molecular Weight Heparin)*
- While **anticoagulation** is important in acute coronary syndromes and would be appropriate to add, the question asks for the **next best step** given the patient's existing management.
- LMWH would typically be added alongside DAPT, but establishing dual antiplatelet therapy takes priority.
*Increase beta blocker dose*
- The patient is already on metoprolol 50 mg, and while **titrating beta-blockers** is important for symptom control and reducing myocardial oxygen demand, the immediate priority in unstable angina is to address the underlying thrombotic process with DAPT.
- Beta-blocker optimization can be done after ensuring adequate antiplatelet therapy.
*IV NTG Drip*
- **Intravenous nitroglycerin (IV NTG)** is used to relieve ongoing chest pain and reduce preload/afterload, especially in severe or refractory symptoms.
- However, the patient's chest discomfort was already **relieved by GTN spray**, indicating that immediate pain control with IV NTG is not the most urgent next step compared to preventing further thrombotic events with DAPT.
*Arrange urgent coronary angiography*
- While **coronary angiography** is indicated in high-risk unstable angina, the immediate next step is to **optimize medical management** with dual antiplatelet therapy.
- Angiography timing depends on risk stratification; in a stable patient already on aspirin, beta-blockers, and statins, adding clopidogrel first ensures optimal antiplatelet coverage before any invasive procedure.
- Early invasive strategy (angiography within 24-72 hours) would be appropriate after medical stabilization.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 9: A 70-year-old man with diabetes, hypertension, and chronic kidney disease (eGFR 35 mL/min/1.73m²) presents with NSTEMI. Troponin is elevated at 8.5 ng/mL. ECG shows 2mm ST depression in V2-V5. GRACE score is 165 (high risk). He is hemodynamically stable. Cardiologist recommends early invasive strategy within 24 hours. Nephrologist is concerned about contrast-induced nephropathy potentially requiring dialysis. Patient is on metformin. Evaluate the management strategy integrating multiple specialist perspectives and evidence.
- A. Proceed with angiography within 24 hours using iso-osmolar contrast and intravenous hydration, hold metformin (Correct Answer)
- B. Perform coronary CT angiography as alternative to invasive angiography
- C. Delay catheterization for 72 hours to optimize renal function with hydration
- D. Prophylactic hemodialysis before and after catheterization to remove contrast
- E. Medical management only with dual antiplatelet therapy, avoid catheterization
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Proceed with angiography within 24 hours using iso-osmolar contrast and intravenous hydration, hold metformin***
- High-risk NSTEMI patients with a **GRACE score >140** benefit from an **early invasive strategy** within 24 hours to reduce ischemic events and mortality.
- Renal protection is maximized through **pre-procedural hydration** and **iso-osmolar contrast**, while **metformin** must be held to avoid the risk of lactic acidosis if acute kidney injury occurs.
*Perform coronary CT angiography as alternative to invasive angiography*
- **Coronary CTA** is primarily used for ruling out coronary artery disease in low-to-intermediate risk stable patients, not for high-risk **NSTEMI**.
- This modality still requires **iodinated contrast** and does not provide the therapeutic benefit of percutaneous coronary intervention (**PCI**).
*Delay catheterization for 72 hours to optimize renal function with hydration*
- Delaying the procedure in a high-risk patient increases the risk of **re-infarction** and **cardiovascular death**, outweighing the minor benefits of prolonged hydration.
- Evidence suggests that optimization of renal status should happen concurrently with the preparation for **early intervention** in high-risk ACS.
*Prophylactic hemodialysis before and after catheterization to remove contrast*
- **Prophylactic hemodialysis** has not been proven to prevent contrast-induced nephropathy and may actually increase the risk of adverse events.
- High-volume **intravenous hydration** with isotonic saline remains the gold standard for preventing renal injury in patients with **CKD**.
*Medical management only with dual antiplatelet therapy, avoid catheterization*
- While **dual antiplatelet therapy** is essential, medical management alone is inferior to an invasive strategy in patients with **high GRACE scores**.
- Avoiding catheterization based solely on **renal impairment** results in "renalism," where patients are undertreated for their life-threatening cardiac condition.
Beta-blockers, ACE-I/ARBs, statins US Medical PG Question 10: A 58-year-old woman with anterior STEMI underwent primary PCI with drug-eluting stent placement. Post-procedure echocardiogram shows left ventricular ejection fraction of 30% with apical akinesis. She is started on aspirin, ticagrelor, high-intensity statin, and ACE inhibitor. On hospital day 3, she develops atrial fibrillation with rapid ventricular response. CHA2DS2-VASc score is 4. Creatinine is normal. Evaluate the optimal antithrombotic strategy balancing ischemic and bleeding risk.
- A. Triple therapy with aspirin, ticagrelor, and apixaban indefinitely
- B. Triple therapy for 6 months, then aspirin and apixaban indefinitely
- C. Aspirin and ticagrelor only, hold anticoagulation due to bleeding risk
- D. Warfarin with INR 2-3 plus aspirin, discontinue ticagrelor
- E. Triple therapy for 1 month, then apixaban and clopidogrel for 11 months, then apixaban alone (Correct Answer)
Beta-blockers, ACE-I/ARBs, statins Explanation: ***Triple therapy for 1 month, then apixaban and clopidogrel for 11 months, then apixaban alone***
- In patients with **Atrial Fibrillation** (CHA2DS2-VASc ≥2) undergoing **PCI**, current guidelines recommend minimizing the duration of **triple therapy** (aspirin, P2Y12 inhibitor, and anticoagulant) to 1 week to 1 month to reduce **bleeding risk**.
- Transitioning to **dual therapy** with a **NOAC** (like apixaban) and a P2Y12 inhibitor (preferably **clopidogrel**) for up to 12 months, followed by NOAC monotherapy, provides an optimal balance between preventing **stent thrombosis** and systemic **thromboembolism**.
*Triple therapy with aspirin, ticagrelor, and apixaban indefinitely*
- Indefinite **triple therapy** carries a prohibitively high risk of life-threatening **major bleeding** without added benefit for stroke prevention.
- **Ticagrelor** is generally avoided in triple therapy regimens due to a significantly higher bleeding profile compared to **clopidogrel**.
*Triple therapy for 6 months, then aspirin and apixaban indefinitely*
- **Triple therapy** for 6 months is rarely indicated and significantly increases the risk of **gastrointestinal and intracranial hemorrhage** compared to the 1-month strategy.
- Aspirin is usually discontinued after the first year in favor of **anticoagulant monotherapy**, as the latter is sufficient for both AF and stable CAD protection.
*Aspirin and ticagrelor only, hold anticoagulation due to bleeding risk*
- This approach leaves the patient with a high **CHA2DS2-VASc score of 4** unprotected against **cardioembolic stroke**, which carries high morbidity and mortality.
- Dual antiplatelet therapy (DAPT) alone is significantly less effective than **oral anticoagulants** for stroke prevention in the setting of atrial fibrillation.
*Warfarin with INR 2-3 plus aspirin, discontinue ticagrelor*
- **NOACs** (like apixaban) are now preferred over **Warfarin** for non-valvular AF due to a superior safety profile, including a lower risk of **intracranial hemorrhage**.
- Discontinuing the P2Y12 inhibitor (ticagrelor) immediately post-PCI in favor of aspirin and warfarin significantly increases the risk of **stent thrombosis**.
More Beta-blockers, ACE-I/ARBs, statins US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
